The Postural Tachycardia Syndrome (POTS): pathophysiology, diagnosis & management

Satish R Raj, Satish R Raj

Abstract

Postural tachycardia syndrome (POTS), characterized by orthostatic tachycardia in the absence of orthostatic hypotension, has been the focus of increasing clinical interest over the last 15 years 1. Patients with POTS complain of symptoms of tachycardia, exercise intolerance, lightheadedness, extreme fatigue, headache and mental clouding. Patients with POTS demonstrate a heart rate increase of >or=30 bpm with prolonged standing (5-30 minutes), often have high levels of upright plasma norepinephrine (reflecting sympathetic nervous system activation), and many patients have a low blood volume. POTS can be associated with a high degree of functional disability. Therapies aimed at correcting the hypovolemia and the autonomic imbalance may help relieve the severity of the symptoms. This review outlines the present understanding of the pathophysiology, diagnosis, and management of POTS.

Figures

Figure 1
Figure 1
Hemodynamics with Upright Posture in POTS The tracings for heart rate, blood pressure, and tilt table angle are shown for a patient with the postural tachycardia syndrome (POTS; left) and for a healthy control subject (right) during a 30 minute tilt head-up test. With head-up tilt, the heart rte immediately increases in POTS and peaks at over 170 bpm prior to the end of the tilt. In contrast the heart rate of the healthy control subject rises to just over 100 bpm. The patient with POTS does not experience a reduction in blood pressure during the tilt test. It is largely unchanged during the test.
Figure 2
Figure 2
Acrocyanosis in POTS One of the more striking physical features in the postural tachycardia syndrome (POTS) is the gross change in dependent skin color that can occur with standing. The panel shows the legs of 2 people who have been standing for 5 minutes, a healthy control subject (left) and a patient with POTS (right). The patient with POTS (right) has significant dark red mottling of her legs extending up to the knees while standing, while the control subject does not have a similar discoloration.
Figure 3
Figure 3
Pathophysiological Schema in POTS There are multiple distinct pathophysiological subtypes within the postural tachycardia syndrome (POTS). The top panel (3a) shows a basal situation with a normal amount of sympathetic nervous system outflow from the brain that activates receptors in the blood vessels (vascular tone & venous return), heart (heart rate & contractility) and kidney (blood volume regulation through renin). Panel 3b shows a schematic of Neuropathic POTS. There is patchy denervation of the sympathetic innervation of the blood vessels in the extremities (especially the legs) and the kidney with subsequent hypovolemia and increased orthostatic venous pooling. This feeds back to the brain to increase sympathetic nervous system outflow in a compensatory effort. This increased sympathoneural flow is sensed most in the heart where there is no denervation. Panel 3c shows a schematic of Central Hyperadrenergic POTS. In this case, the underlying problem is excessive sympathetic nervous outflow from the brain that affects the blood vessels, kidneys and the heart. In addition to tachycardia, this form of POTS is often associated with orthostatic hypertension.
Figure 3
Figure 3
Pathophysiological Schema in POTS There are multiple distinct pathophysiological subtypes within the postural tachycardia syndrome (POTS). The top panel (3a) shows a basal situation with a normal amount of sympathetic nervous system outflow from the brain that activates receptors in the blood vessels (vascular tone & venous return), heart (heart rate & contractility) and kidney (blood volume regulation through renin). Panel 3b shows a schematic of Neuropathic POTS. There is patchy denervation of the sympathetic innervation of the blood vessels in the extremities (especially the legs) and the kidney with subsequent hypovolemia and increased orthostatic venous pooling. This feeds back to the brain to increase sympathetic nervous system outflow in a compensatory effort. This increased sympathoneural flow is sensed most in the heart where there is no denervation. Panel 3c shows a schematic of Central Hyperadrenergic POTS. In this case, the underlying problem is excessive sympathetic nervous outflow from the brain that affects the blood vessels, kidneys and the heart. In addition to tachycardia, this form of POTS is often associated with orthostatic hypertension.
Figure 3
Figure 3
Pathophysiological Schema in POTS There are multiple distinct pathophysiological subtypes within the postural tachycardia syndrome (POTS). The top panel (3a) shows a basal situation with a normal amount of sympathetic nervous system outflow from the brain that activates receptors in the blood vessels (vascular tone & venous return), heart (heart rate & contractility) and kidney (blood volume regulation through renin). Panel 3b shows a schematic of Neuropathic POTS. There is patchy denervation of the sympathetic innervation of the blood vessels in the extremities (especially the legs) and the kidney with subsequent hypovolemia and increased orthostatic venous pooling. This feeds back to the brain to increase sympathetic nervous system outflow in a compensatory effort. This increased sympathoneural flow is sensed most in the heart where there is no denervation. Panel 3c shows a schematic of Central Hyperadrenergic POTS. In this case, the underlying problem is excessive sympathetic nervous outflow from the brain that affects the blood vessels, kidneys and the heart. In addition to tachycardia, this form of POTS is often associated with orthostatic hypertension.
Figure 4
Figure 4
Blood Volume Deviation in POTS The 3 panels show the blood volumes of control subjects and patients with POTS compared to hat expected based on their individual height, weight and gender. Data are shown for plasma volume (PV; Panel A), red cell volume (RC; Panel B) and total blood volume (TBV; Panel C). The plasma volume and total blood volume of the control subjects was similar to their expected values. The patients with POT had a deficit of their plasma volume (Panel A), red cell volume (Panel B) and total blood volume (Panel C) compared to the control group. Figures adapted with data from Raj SR, Biaggioni I, Yamhure PC, Black BK, Paranjape SY, Byrne D, Robertson D. The Renin-Aldosterone Paradox and Perturbed Blood Volume Regulation Underlying the Postural Tachycardia Syndrome. Circulation 2005; 111:1574-1582.

References

    1. Low PA, Opfer-Gehrking TL, Textor SC, et al. Rummans TA. Postural tachycardia syndrome (POTS) Neurology. 1995;45:S19–S25.
    1. Wooley CF. Where are the diseases of yesteryear? DaCosta's syndrome, soldiers heart, the effort syndrome, neurocirculatory asthenia--and the mitral valve prolapse syndrome. Circulation. 1976;53:749–751.
    1. Miller JW, Streeten DH. Vascular responsiveness to norepinephrine in sympathicotonic orthostatic intolerance. J Lab Clin Med. 1990;115:549–558.
    1. Wieling W, Shepherd JT. Initial and delayed circulatory responses to orthostatic stress in normal humans and in subjects with orthostatic intolerance. Int Angiol. 1992;11:69–82.
    1. Raj SR, Biaggioni I, Yamhure PC, et al. Renin-aldosterone paradox and perturbed blood volume regulation underlying postural tachycardia syndrome. Circulation. 2005;111:1574–1582.
    1. Friesinger GC, Biern RO, Likar I, et al. Exercise electrocardiography and vasoregulatory abnormalities. Am J Cardiol. 1972;30:733–740.
    1. Fu Q, Witkowski S, Okazaki K, et al. Effects of gender and hypovolemia on sympathetic neural responses to orthostatic stress. Am J Physiol Regul Integr Comp Physiol. 2005;289:R109–R116.
    1. Gazit Y, Nahir AM, Grahame R, et al. Dysautonomia in the joint hypermobility syndrome. Am J Med. 2003;115:33–40.
    1. Khurana RK, Peters RW. Orthostatic intolerance and orthostatic tachycardia: a heterogeneous disorder. Clin Auton Res. 1995;5:12–18.
    1. Beck AT, Epstein N, Brown G, et al. An inventory for measuring clinical anxiety: psychometric properties. J Consult Clin Psychol. 1988;56:893–897.
    1. Raj V, Haman K, Raj S, et al. Psychiatric profile and attention deficits in the postural tachycardia syndrome. Clin Auton Res. 2004;14:309.
    1. Peterson RA, Reiss S. Anxiety Sensitivity Index Manual. Worthington, OH: International Diagnostic Systems; 1992.
    1. Conners CK, Erhardt D, Sparrow E. Conner's adult ADHD rating scales (CAARS) technical manual. Multi-Health System, Inc; 1999.
    1. Streeten DH, Anderson GH., Jr Delayed orthostatic intolerance. Arch Intern Med. 1992;152:1066–1072.
    1. Raj SR, Garland EM, Biaggioni I, et al. Morning heart rate surge in postural tachycardia syndrome. Circulation. 2005;112:U810.
    1. Freeman R, Lirofonis V, Farquhar WB, et al. Limb venous compliance in patients with idiopathic orthostatic intolerance and postural tachycardia. J Appl Physiol. 2002;93:636–644.
    1. Stewart JM. Pooling in chronic orthostatic intolerance: arterial vasoconstrictive but not venous compliance defects. Circulation. 2002;105:2274–2281.
    1. Streeten DH. Orthostatic disorders of the circulation: Mechanisms, manifestations and treatment. New York: Plenum Medical Book Publishing; 1987.
    1. Raj SR, Dzurik MV, Biaggioni I, et al. Diagnosing postural tachycardia syndrome: comparison of tilt versus standing. Circulation. 2005;112:U765.
    1. Shibao C, Arzubiaga C, Roberts LJ, et al. Hyperadrenergic postural tachycardia syndrome in mast cell activation disorders. Hypertension. 2005;45:385–390.
    1. Manger WM, Eisenhofer G. Pheochromocytoma: diagnosis and management update. Curr Hypertens Rep. 2004;6:477–484.
    1. Schondorf R, Low PA. Idiopathic postural orthostatic tachycardia syndrome: an attenuated form of acute pandysautonomia? Neurology. 1993;43:132–137.
    1. Hoeldtke RD, Davis KM. The orthostatic tachycardia syndrome: evaluation of autonomic function and treatment with octreotide and ergot alkaloids. J Clin Endocrinol Metab. 1991;73:132–139.
    1. Streeten DH. Pathogenesis of hyperadrenergic orthostatic hypotension. Evidence of disordered venous innervation exclusively in the lower limbs. J Clin Invest. 1990;86:1582–1588.
    1. Singer W, Spies JM, McArthur J, et al. Prospective evaluation of somatic and autonomic small fibers in selected autonomic neuropathies. Neurology. 2004;62:612–618.
    1. Jacob G, Costa F, Shannon JR, et al. The neuropathic postural tachycardia syndrome. N Engl J Med. 2000;343:1008–1014.
    1. Jacob G, Robertson D, Mosqueda-Garcia R, et al. Hypovolemia in syncope and orthostatic intolerance role of the renin-angiotensin system. Am J Med. 1997;103:128–133.
    1. Fouad FM, Tadena-Thome L, Bravo EL, et al. Idiopathic hypovolemia. Ann Intern Med. 1986;104:298–303.
    1. Streeten DH, Thomas D, Bell DS, et al. The roles of orthostatic hypotension, orthostatic tachycardia, and subnormal erythrocyte volume in the pathogenesis of the chronic fatigue syndrome. Am J Med Sci. 2000;320:1–8.
    1. Shannon JR, Flattem NL, Jordan J, et al. Orthostatic intolerance and tachycardia associated with norepinephrine-transporter deficiency. N Engl J Med. 2000;342:541–549.
    1. Vincent S, Bieck PR, Garland EM, et al. Clinical assessment of norepinephrine transporter blockade through biochemical and pharmacological profiles. Circulation. 2004;109:3202–3207.
    1. Schroeder C, Tank J, Boschmann M, et al. Selective norepinephrine reuptake inhibition as a human model of orthostatic intolerance. Circulation. 2002;105:347–353.
    1. Raj SR, Vincent S, Black BK, et al. Postural tachycardia syndrome: 2 contrasting pharmacological models. Heart Rhythm. 2004;13:S101.
    1. Arzubiaga C, Morrow J, Roberts J, et al. Neuropeptide Y, a putative cotransmitter in noradrenergic neurons, induces mast cell degranulation but not prostaglandin D2 release. J Allergy Clin Immunol. 1991;87:88–93.
    1. Shannon JR, Diedrich A, Biaggioni I, et al. Water drinking as a treatment for orthostatic syndromes. Am J Med. 2002;112:355–360.
    1. Winker R, Barth A, Bidmon D, et al. Endurance exercise training in orthostatic intolerance: a randomized, controlled trial. Hypertension. 2005;45:391–398.
    1. Jacob G, Shannon JR, Black B, et al. Effects of volume loading and pressor agents in idiopathic orthostatic tachycardia. Circulation. 1997;96:575–580.
    1. Biaggioni I, Robertson D, Krantz S, et al. The anemia of primary autonomic failure and its reversal with recombinant erythropoietin. Ann Intern Med. 1994;121:181–186.
    1. Jacob G, Biaggioni I. Idiopathic orthostatic intolerance and postural tachycardia syndromes. Am J Med Sci. 1999;317:88–101.
    1. Grubb BP, Karas B, Kosinski D, et al. Preliminary observations on the use of midodrine hydrochloride in the treatment of refractory neurocardiogenic syncope. J Interv Card. 1999;3:139–143.
    1. Taneja I, Diedrich A, Black BK, et al. Modafinil elicits sympathomedullary activation. Hypertension. 2005;45:612–618.

Source: PubMed

3
Subskrybuj